Trials / Completed
CompletedNCT03635606
GUARD-AKI: Validation of AKI-Sapere in Cardiac Surgery Patients
Validation of AKI-Sapere Model to Predict Patients at Risk for AKI After Cardiac Surgery: GUARD-AKI (GUiding Against Reserve Decline)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 370 (actual)
- Sponsor
- Sapere Bio · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
Cardiac surgery associated acute kidney injury (CSA-AKI) has been recognized as the second most common cause of hospital acquired AKI. The development of CSA-AKI is independently associated with an increased risk of in-hospital death. There are currently no biomarkers that could identify patients at higher risk for AKI and current risk predictor scores that are based on clinical and demographic information are inadequate. Therefore, a diagnostic test for predicting AKI risk in this clinical context would assist clinicians to optimize surgical strategy and postoperative care to prevent CSA-AKI occurrence and improve patient outcomes. The primary purpose of this study is to validate a panel of biomarkers identified in the discovery study (referred to as AKI-Sapere prognostic) to identify patients at risk for all stages of CSA-AKI.
Conditions
Timeline
- Start date
- 2020-02-24
- Primary completion
- 2022-09-01
- Completion
- 2023-02-28
- First posted
- 2018-08-17
- Last updated
- 2023-04-04
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03635606. Inclusion in this directory is not an endorsement.